Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

STRO - Sutro Biopharma Inc


IEX Last Trade
4.57
0.040   0.875%

Share volume: 323,512
Last Updated: Fri 30 Aug 2024 09:59:56 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$4.53
0.04
0.88%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
25%
Profitability 25%
Dept financing 17%
Liquidity 74%
Performance 15%
Company vs Stock growth
vs
Performance
5 Days
-8.78%
1 Month
12.29%
3 Months
5.54%
6 Months
-10.22%
1 Year
-5.77%
2 Year
-19.68%
Key data
Stock price
$4.57
P/E Ratio 
-3.01
DAY RANGE
$4.44 - N/A
EPS 
-$1.88
52 WEEK RANGE
$2.01 - $6.13
52 WEEK CHANGE
$0.02
MARKET CAP 
374.574 M
YIELD 
N/A
SHARES OUTSTANDING 
81.964 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
BETA 
1.81
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$501,154
AVERAGE 30 VOLUME 
$628,600
Company detail
CEO: William Newell
Region: US
Website: http://www.sutrobio.com/
Employees: 260
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

at sutro biopharma we have pioneered a compelling and unique way of discovering, developing and manufacturing therapeutics. our focus is aimed primarily on next generation cancer therapeutics — antibody conjugates and bispecific antibodies. unconstrained by traditional methods of cell-based discovery, we can design and develop targeted medicines by innovating outside the constraints of the cell. our technology enables us to iteratively discover and test molecules in a rapid cycle of weeks rather than months, to rapidly identify the optimal molecule designed for safety and potency. our approach to discovery, without the cell, is also transcending the the limitations of biologics manufacturing. sutro has the world’s only cgmp cell-free manufacturing facility located in san carlos, california. this state-of- the-art facility confers an important competitive advantage as we head into human clinical trials in 2018. in addition to developing our own oncology pipeline, sutro biopharma is coll

Recent news